Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Small noncoding RNA TY2 enhances efferocytosis and improves outcomes in a mouse model of sepsis
Alessandra Ciullo, Xaviar M. Jones, Hiroaki Komuro, Liang Li, Anh Nguyen, Eduardo Marbán, Ahmed Gamal-Eldin Ibrahim
Alessandra Ciullo, Xaviar M. Jones, Hiroaki Komuro, Liang Li, Anh Nguyen, Eduardo Marbán, Ahmed Gamal-Eldin Ibrahim
View: Text | PDF
Research Letter Cardiology Inflammation

Small noncoding RNA TY2 enhances efferocytosis and improves outcomes in a mouse model of sepsis

  • Text
  • PDF
Abstract

Authors

Alessandra Ciullo, Xaviar M. Jones, Hiroaki Komuro, Liang Li, Anh Nguyen, Eduardo Marbán, Ahmed Gamal-Eldin Ibrahim

×

Figure 1

TY2 is protective in a rat model of MI and in a model of cecal ligation and puncture–induced sepsis.

Options: View larger image (or click on image) Download as PowerPoint
TY2 is protective in a rat model of MI and in a model of cecal ligation ...
(A) Schematic of two-step structure activity screening using yREX3 as a template. Locked nucleic acids are shown in red. (B) Pick1 downregulation screening of synthetic candidates. (C) Stability of yREX3 and TY2 exposed to increasing concentrations of RNAse R. (D) Efferocytosis assay showing uptake of DiD-labeled dead rat cardiomyocytes by rat macrophages at 48 hours. (E–G) TTC staining showing infarct size (E and F) and ELISA of circulating cardiac troponin I (cTnI) (G) in rats with MI receiving yREX3 or TY2 i.v. or orally by gavage after reperfusion. (H) Cecal ligation and puncture–induced (CLP-induced) polymicrobial sepsis model was induced at day 0. Numbers represent days. (I) Kaplan-Meier curve showing survival of treatment groups (sham, n = 5; vehicle, n = 8; TY2, n = 9). (J) Echocardiographic measurement of cardiac function (fractional shortening [FS] %) at day 1 and day 7. (K) Left ventricular internal diameter (LVID; mm). (L) Bacterial burden in tissue measured in hearts (L) and lungs (M) using qPCR of bacterial 16S. (N and O) Assessment of bacterial (E. coli) clearance by bone marrow–derived macrophages exposed to vehicle or TY2. Scale bar: 200 μm. (P and Q) PSMAD3 and CD68 expression in heart sections of mice receiving vehicle or TY2 at 72 hours. Scale bar: 100 μm. Data are presented as mean ± SEM. Dots represent single animals. Statistical analysis of two groups was by Student’s unpaired 2-tailed t test, with 95% CI (C, N, and Q) and that of 3 or more groups was by 1-way ANOVA with Tukey’s (D, J, and K) or Dunnett’s (B, F, G, L, and M, vs. Veh) post test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts